Literature DB >> 31237643

Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality.

Surya P Bhatt1, Pallavi P Balte2, Joseph E Schwartz2, Patricia A Cassano3, David Couper4, David R Jacobs5, Ravi Kalhan6, George T O'Connor7, Sachin Yende8, Jason L Sanders9, Jason G Umans10, Mark T Dransfield1, Paulo H Chaves11, Wendy B White12, Elizabeth C Oelsner2,13.   

Abstract

Importance: According to numerous current guidelines, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of the forced expiratory volume in the first second to the forced vital capacity (FEV1:FVC) of less than 0.70, yet this fixed threshold is based on expert opinion and remains controversial. Objective: To determine the discriminative accuracy of various FEV1:FVC fixed thresholds for predicting COPD-related hospitalization and mortality. Design, Setting, and Participants: The National Heart, Lung, and Blood Institute (NHLBI) Pooled Cohorts Study harmonized and pooled data from 4 US general population-based cohorts (Atherosclerosis Risk in Communities Study; Cardiovascular Health Study; Health, Aging, and Body Composition Study; and Multi-Ethnic Study of Atherosclerosis). Participants aged 45 to 102 years were enrolled from 1987 to 2000 and received follow-up longitudinally through 2016. Exposures: Presence of airflow obstruction, which was defined by a baseline FEV1:FVC less than a range of fixed thresholds (0.75 to 0.65) or less than the lower limit of normal as defined by Global Lung Initiative reference equations (LLN). Main Outcomes and Measures: The primary outcome was a composite of COPD hospitalization and COPD-related mortality, defined by adjudication or administrative criteria. The optimal fixed FEV1:FVC threshold was defined by the best discrimination for these COPD-related events as indexed using the Harrell C statistic from unadjusted Cox proportional hazards models. Differences in C statistics were compared with respect to less than 0.70 and less than LLN thresholds using a nonparametric approach.
Results: Among 24 207 adults in the pooled cohort (mean [SD] age at enrollment, 63 [10.5] years; 12 990 [54%] women; 16 794 [69%] non-Hispanic white; 15 181 [63%] ever smokers), complete follow-up was available for 11 077 (77%) at 15 years. During a median follow-up of 15 years, 3925 participants experienced COPD-related events over 340 757 person-years of follow-up (incidence density rate, 11.5 per 1000 person-years), including 3563 COPD-related hospitalizations and 447 COPD-related deaths. With respect to discrimination of COPD-related events, the optimal fixed threshold (0.71; C statistic for optimal fixed threshold, 0.696) was not significantly different from the 0.70 threshold (difference, 0.001 [95% CI, -0.002 to 0.004]) but was more accurate than the LLN threshold (difference, 0.034 [95% CI, 0.028 to 0.041]). The 0.70 threshold provided optimal discrimination in the subgroup analysis of ever smokers and in adjusted models. Conclusions and Relevance: Defining airflow obstruction as FEV1:FVC less than 0.70 provided discrimination of COPD-related hospitalization and mortality that was not significantly different or was more accurate than other fixed thresholds and the LLN. These results support the use of FEV1:FVC less than 0.70 to identify individuals at risk of clinically significant COPD.

Entities:  

Mesh:

Year:  2019        PMID: 31237643      PMCID: PMC6593636          DOI: 10.1001/jama.2019.7233

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  39 in total

1.  Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis.

Authors:  H K Genant; C Cooper; G Poor; I Reid; G Ehrlich; J Kanis; B E Nordin; E Barrett-Connor; D Black; J P Bonjour; B Dawson-Hughes; P D Delmas; J Dequeker; S Ragi Eis; C Gennari; O Johnell; C C Johnston; E M Lau; U A Liberman; R Lindsay; T J Martin; B Masri; C A Mautalen; P J Meunier; N Khaltaev
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study.

Authors:  B H Goodpaster; C L Carlson; M Visser; D E Kelley; A Scherzinger; T B Harris; E Stamm; A B Newman
Journal:  J Appl Physiol (1985)       Date:  2001-06

3.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

4.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

5.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

6.  Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?

Authors:  David M Mannino; A Sonia Buist; William M Vollmer
Journal:  Thorax       Date:  2006-11-07       Impact factor: 9.139

7.  Cardiovascular morbidity and mortality in COPD.

Authors:  Laetitia Huiart; Pierre Ernst; Samy Suissa
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

8.  Assessing the performance of prediction models: a framework for traditional and novel measures.

Authors:  Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

9.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

10.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000.

Authors:  David M Mannino; David M Homa; Lara J Akinbami; Earl S Ford; Stephen C Redd
Journal:  MMWR Surveill Summ       Date:  2002-08-02
View more
  44 in total

1.  Deep neural network analyses of spirometry for structural phenotyping of chronic obstructive pulmonary disease.

Authors:  Sandeep Bodduluri; Arie Nakhmani; Joseph M Reinhardt; Carla G Wilson; Merry-Lynn McDonald; Ramaraju Rudraraju; Byron C Jaeger; Nirav R Bhakta; Peter J Castaldi; Frank C Sciurba; Chengcui Zhang; Purushotham V Bangalore; Surya P Bhatt
Journal:  JCI Insight       Date:  2020-07-09

Review 2.  Fifty Years of Progress in the Epidemiology of Chronic Obstructive Pulmonary Disease: A Review of National Heart, Lung, and Blood Institute-Sponsored Studies.

Authors:  David M Mannino
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

3.  COPD Patients Have a Restricted Breathing Pattern That Persists with Increased Metabolic Demands.

Authors:  Jennifer M Yentes; Farahnaz Fallahtafti; William Denton; Stephen I Rennard
Journal:  COPD       Date:  2020-04-17       Impact factor: 2.409

4.  "High-Risk" Clinical and Inflammatory Clusters in COPD of Chinese Descent.

Authors:  Pei Yee Tiew; Fanny Wai San Ko; Jayanth Kumar Narayana; Mau Ern Poh; Huiying Xu; Han Yee Neo; Li-Cher Loh; Choo Khoon Ong; Micheál Mac Aogáin; Jessica Han Ying Tan; Nabilah Husna Kamaruddin; Gerald Jiong Hui Sim; Therese S Lapperre; Mariko Siyue Koh; David Shu Cheong Hui; John Arputhan Abisheganaden; Augustine Tee; Krasimira Tsaneva-Atanasova; Sanjay H Chotirmall
Journal:  Chest       Date:  2020-02-22       Impact factor: 9.410

5.  Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD.

Authors:  Aparna Balasubramanian; Todd M Kolb; Rachel L Damico; Paul M Hassoun; Meredith C McCormack; Stephen C Mathai
Journal:  Chest       Date:  2020-03-14       Impact factor: 9.410

6.  Association of Nonobstructive Chronic Bronchitis With Respiratory Health Outcomes in Adults.

Authors:  Pallavi P Balte; Paulo H M Chaves; David J Couper; Paul Enright; David R Jacobs; Ravi Kalhan; Richard A Kronmal; Laura R Loehr; Stephanie J London; Anne B Newman; George T O'Connor; Joseph E Schwartz; Benjamin M Smith; Lewis J Smith; Wendy B White; Sachin Yende; Elizabeth C Oelsner
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873

7.  Update in Chronic Obstructive Pulmonary Disease 2020.

Authors:  Andy I Ritchie; Jonathon R Baker; Trisha M Parekh; James P Allinson; Surya P Bhatt; Louise E Donnelly; Gavin C Donaldson
Journal:  Am J Respir Crit Care Med       Date:  2021-07-01       Impact factor: 21.405

8.  COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.

Authors:  Katherine E Lowe; Elizabeth A Regan; Antonio Anzueto; Erin Austin; John H M Austin; Terri H Beaty; Panayiotis V Benos; Christopher J Benway; Surya P Bhatt; Eugene R Bleecker; Sandeep Bodduluri; Jessica Bon; Aladin M Boriek; Adel Re Boueiz; Russell P Bowler; Matthew Budoff; Richard Casaburi; Peter J Castaldi; Jean-Paul Charbonnier; Michael H Cho; Alejandro Comellas; Douglas Conrad; Corinne Costa Davis; Gerard J Criner; Douglas Curran-Everett; Jeffrey L Curtis; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Jennifer G Dy; Ashraf Fawzy; Margaret Fleming; Eric L Flenaugh; Marilyn G Foreman; Spyridon Fortis; Hirut Gebrekristos; Sarah Grant; Philippe A Grenier; Tian Gu; Abhya Gupta; MeiLan K Han; Nicola A Hanania; Nadia N Hansel; Lystra P Hayden; Craig P Hersh; Brian D Hobbs; Eric A Hoffman; James C Hogg; John E Hokanson; Karin F Hoth; Albert Hsiao; Stephen Humphries; Kathleen Jacobs; Francine L Jacobson; Ella A Kazerooni; Victor Kim; Woo Jin Kim; Gregory L Kinney; Harald Koegler; Sharon M Lutz; David A Lynch; Neil R MacIntye; Barry J Make; Nathaniel Marchetti; Fernando J Martinez; Diego J Maselli; Anne M Mathews; Meredith C McCormack; Merry-Lynn N McDonald; Charlene E McEvoy; Matthew Moll; Sarah S Molye; Susan Murray; Hrudaya Nath; John D Newell; Mariaelena Occhipinti; Matteo Paoletti; Trisha Parekh; Massimo Pistolesi; Katherine A Pratte; Nirupama Putcha; Margaret Ragland; Joseph M Reinhardt; Stephen I Rennard; Richard A Rosiello; James C Ross; Harry B Rossiter; Ingo Ruczinski; Raul San Jose Estepar; Frank C Sciurba; Jessica C Sieren; Harjinder Singh; Xavier Soler; Robert M Steiner; Matthew J Strand; William W Stringer; Ruth Tal-Singer; Byron Thomashow; Gonzalo Vegas Sánchez-Ferrero; John W Walsh; Emily S Wan; George R Washko; J Michael Wells; Chris H Wendt; Gloria Westney; Ava Wilson; Robert A Wise; Andrew Yen; Kendra Young; Jeong Yun; Edwin K Silverman; James D Crapo
Journal:  Chronic Obstr Pulm Dis       Date:  2019-11

9.  Randomization to Omega-3 Fatty Acid Supplementation and Endothelial Function in COPD: The COD-Fish Randomized Controlled Trial.

Authors:  John S Kim; Michael A Thomashow; Natalie H Yip; Kristin M Burkart; Christian M Lo Cascio; Daichi Shimbo; R Graham Barr
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

10.  The Heterogeneity of COPD Patients in a Community-Based Practice and the Inadequacy of the Global Initiative for Chronic Obstructive Lung Disease Criteria: A Real-World Experience.

Authors:  Fortune O Alabi; Hadaya A Alkhateeb; Kayla M DeBarros; Pierina S Barletti Benel; Rachel L Sanchez-Martez; Mia L Zeper; Reema A Ismail; Fred Umeh; Nelson Medina-Villanueva
Journal:  Chronic Obstr Pulm Dis       Date:  2021-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.